NASDAQ:AXSM - Axsome Therapeutics Stock Price, Price Target & More

$2.55 0.00 (0.00 %)
(As of 04/22/2018 04:57 AM ET)
Previous Close$2.55
Today's Range$2.45 - $2.65
52-Week Range$2.05 - $6.45
Volume163,392 shs
Average Volume141,457 shs
Market Capitalization$65.01 million
P/E Ratio-2.06
Dividend YieldN/A
Beta-0.16

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics logoAxsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The company's product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimer's disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for Phase 2 trial of AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXSM
CUSIPN/A
Phone212-332-3241

Debt

Debt-to-Equity Ratio0.40%
Current Ratio2.90%
Quick Ratio2.90%

Price-To-Earnings

Trailing P/E Ratio-2.06
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book3.86

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-28,940,000.00
Net MarginsN/A
Return on Equity-132.28%
Return on Assets-73.69%

Miscellaneous

Employees25
Outstanding Shares25,490,000

How to Become a New Pot Stock Millionaire

Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics (NASDAQ:AXSM) issued its earnings results on Wednesday, March, 7th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.04. View Axsome Therapeutics' Earnings History.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Axsome Therapeutics.

What price target have analysts set for AXSM?

4 brokerages have issued 12-month price objectives for Axsome Therapeutics' shares. Their forecasts range from $13.00 to $31.00. On average, they anticipate Axsome Therapeutics' share price to reach $19.50 in the next year. View Analyst Ratings for Axsome Therapeutics.

Who are some of Axsome Therapeutics' key competitors?

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the folowing people:
  • Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 50)
  • Ms. Constance Ames, VP of Fin. & Treasurer (Age 32)
  • Dr. Randall E. Kaye M.D., Sr. Clinical Advisor (Age 56)
  • Mr. John Golubieski, Chief Financial Officer (Age 53)
  • Mr. Mark Jacobson M.A., VP of Operations and Sec. (Age 35)

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Has Axsome Therapeutics been receiving favorable news coverage?

Headlines about AXSM stock have been trending somewhat positive on Sunday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a media sentiment score of 0.17 on Accern's scale. They also assigned news articles about the company an impact score of 46.23 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $2.55.

How big of a company is Axsome Therapeutics?

Axsome Therapeutics has a market capitalization of $65.01 million. The company earns $-28,940,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Axsome Therapeutics employs 25 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.


MarketBeat Community Rating for Axsome Therapeutics (AXSM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Axsome Therapeutics (NASDAQ:AXSM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Axsome Therapeutics in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 664.71%. The high price target for AXSM is $31.00 and the low price target for AXSM is $13.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.50$19.50$19.50$19.50
Price Target Upside: 664.71% upside245.13% upside245.13% upside242.11% upside

Axsome Therapeutics (NASDAQ:AXSM) Consensus Price Target History

Price Target History for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ:AXSM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/1/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
7/26/2017Ladenburg ThalmannReiterated RatingBuy$28.00 -> $31.00HighView Rating Details
6/20/2017AegisReiterated RatingBuy$20.00HighView Rating Details
5/19/2017BTIG ResearchInitiated CoverageBuy$14.00HighView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$20.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Axsome Therapeutics (NASDAQ:AXSM) Earnings History and Estimates Chart

Earnings by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ:AXSM) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.26 EPS

Axsome Therapeutics (NASDAQ AXSM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.30)N/AView Earnings Details
3/7/2018Q4 2017($0.32)($0.28)ViewListenView Earnings Details
11/8/2017Q3 2017($0.27)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.31)($0.30)ViewN/AView Earnings Details
5/9/20173/31/2017($0.40)($0.41)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.38)ViewN/AView Earnings Details
11/14/2016Q3($0.39)($0.38)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.39)($0.36)ViewN/AView Earnings Details
5/11/2016Q116($0.28)($0.31)ViewN/AView Earnings Details
3/24/2016Q416($0.22)($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Axsome Therapeutics (NASDAQ:AXSM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Axsome Therapeutics (NASDAQ AXSM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 35.20%
Institutional Ownership Percentage: 22.84%
Insider Trading History for Axsome Therapeutics (NASDAQ:AXSM)
Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ AXSM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2015Randall KayeInsiderBuy1,000$9.03$9,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Axsome Therapeutics (NASDAQ AXSM) News Headlines

Source:
DateHeadline
BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial OfficerBRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer
www.reuters.com - April 20 at 10:13 AM
Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?
finance.yahoo.com - April 20 at 10:13 AM
Axsome Therapeutics appoints Nick Pizzie as CFOAxsome Therapeutics appoints Nick Pizzie as CFO
seekingalpha.com - April 19 at 4:13 PM
Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial OfficerAxsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer
feeds.benzinga.com - April 19 at 7:34 AM
Axsome Therapeutics (AXSM) Given Average Recommendation of "Hold" by BrokeragesAxsome Therapeutics (AXSM) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 19 at 3:40 AM
Axsome Therapeutics (AXSM) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowAxsome Therapeutics (AXSM) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:06 PM
Axsome Therapeutics (AXSM) Presents At Needham and Company 17th Annual Healthcare Conference - SlideshowAxsome Therapeutics (AXSM) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:01 PM
Axsome therapeutics to host R&D day focused on AXS-05 and unmet needs in depression, alzheimer’s disease agitation, and nicotine dependenceAxsome therapeutics to host R&D day focused on AXS-05 and unmet needs in depression, alzheimer’s disease agitation, and nicotine dependence
seekingalpha.com - March 27 at 10:12 AM
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceAxsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
finance.yahoo.com - March 27 at 10:12 AM
Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences ConferenceAxsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - March 26 at 10:50 AM
Axsome Therapeutics (AXSM) Upgraded to Sell by ValuEngineAxsome Therapeutics (AXSM) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - March 25 at 8:45 PM
Axsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Hold" by AnalystsAxsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 25 at 3:30 AM
Axsome Therapeutics (AXSM) Downgraded by Zacks Investment Research to SellAxsome Therapeutics (AXSM) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 13 at 5:48 PM
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the ... - GlobeNewswire (press release)Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 4:16 PM
Head to Head Survey: Axsome Therapeutics (AXSM) versus GW Pharmaceuticals PLC- (GWPH)Head to Head Survey: Axsome Therapeutics (AXSM) versus GW Pharmaceuticals PLC- (GWPH)
www.americanbankingnews.com - March 13 at 3:02 AM
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental NeurotherapeuticsAxsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
finance.yahoo.com - March 12 at 4:01 PM
Axsome Therapeutics (AXSM) Releases  Earnings Results, Beats Estimates By $0.04 EPSAxsome Therapeutics (AXSM) Releases Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - March 8 at 10:56 AM
Axsome Therapeutics, Inc. to Host Earnings CallAxsome Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 10:53 AM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateAxsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 7 at 10:53 AM
Axsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Buy" by BrokeragesAxsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 28 at 3:32 AM
Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and DextromethorphanAxsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan
finance.yahoo.com - February 26 at 10:12 AM
Axsome Therapeutics (AXSM) Scheduled to Post Earnings on MondayAxsome Therapeutics (AXSM) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 26 at 3:20 AM
Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm?Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - February 15 at 6:01 AM
Axsome Therapeutics Inc (AXSM) Receives Average Rating of "Buy" from BrokeragesAxsome Therapeutics Inc (AXSM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 3 at 3:26 AM
Axsome Therapeutics Inc (AXSM) Sees Large Increase in Short InterestAxsome Therapeutics Inc (AXSM) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 28 at 1:26 AM
Mid-Day Market Update: Dow Surges Over 100 Points; e.l.f. Beauty Shares DropMid-Day Market Update: Dow Surges Over 100 Points; e.l.f. Beauty Shares Drop
www.nasdaq.com - January 9 at 3:40 PM
Mid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses ViewsMid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses Views
www.benzinga.com - January 9 at 11:10 AM
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 TrialAxsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
finance.yahoo.com - January 9 at 11:10 AM
Axsome Therapeutics Inc (AXSM) Receives Consensus Rating of "Buy" from AnalystsAxsome Therapeutics Inc (AXSM) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 5:38 AM
Critical Survey: Axsome Therapeutics (AXSM) versus The CompetitionCritical Survey: Axsome Therapeutics (AXSM) versus The Competition
www.americanbankingnews.com - January 2 at 11:10 PM
Axsome Therapeutics (AXSM) Upgraded to "Buy" at Zacks Investment ResearchAxsome Therapeutics (AXSM) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 1 at 5:20 PM
Axsome Therapeutics Target of Unusually Large Options Trading (AXSM)Axsome Therapeutics Target of Unusually Large Options Trading (AXSM)
www.americanbankingnews.com - December 31 at 2:40 AM
Axsome Therapeutics (AXSM) Downgraded to Hold at Zacks Investment ResearchAxsome Therapeutics (AXSM) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - December 29 at 7:18 PM
Analyzing Axsome Therapeutics (AXSM) and Its PeersAnalyzing Axsome Therapeutics (AXSM) and Its Peers
www.americanbankingnews.com - December 26 at 5:48 AM
Axsome Therapeutics to Present at Biotech Showcase 2018 - GlobeNewswire (press release)Axsome Therapeutics to Present at Biotech Showcase 2018 - GlobeNewswire (press release)
globenewswire.com - December 21 at 11:28 AM
Reviewing Axsome Therapeutics (AXSM) and Its RivalsReviewing Axsome Therapeutics (AXSM) and Its Rivals
www.americanbankingnews.com - December 20 at 7:32 AM
Axsome Therapeutics to Present at Biotech Showcase 2018Axsome Therapeutics to Present at Biotech Showcase 2018
finance.yahoo.com - December 19 at 11:23 AM
Axsome Therapeutics Inc (AXSM) Given Consensus Rating of "Buy" by BrokeragesAxsome Therapeutics Inc (AXSM) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 15 at 3:32 AM
Axsome Therapeutics (AXSM) Rating Increased to Buy at Zacks Investment ResearchAxsome Therapeutics (AXSM) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - December 14 at 4:56 PM
Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking CessationAxsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation
finance.yahoo.com - December 14 at 11:34 AM
Zacks Investment Research Downgrades Axsome Therapeutics (AXSM) to HoldZacks Investment Research Downgrades Axsome Therapeutics (AXSM) to Hold
www.americanbankingnews.com - December 13 at 4:46 PM
Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering - GlobeNewswire (press release)Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - December 6 at 8:46 AM
Axsome Therapeutics (AXSM) Reports 1.78M Share Registered Direct Offering Priced at the Market - StreetInsider.comAxsome Therapeutics (AXSM) Reports 1.78M Share Registered Direct Offering Priced at the Market - StreetInsider.com
www.streetinsider.com - December 3 at 3:40 PM
Cantor Fitzgerald Analysts Give Axsome Therapeutics (AXSM) a $13.00 Price TargetCantor Fitzgerald Analysts Give Axsome Therapeutics (AXSM) a $13.00 Price Target
www.americanbankingnews.com - December 1 at 6:24 PM
Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-MarketAxsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-Market
finance.yahoo.com - December 1 at 5:58 PM
Axsome Therapeutics, Inc. (AXSM) Receives Consensus Recommendation of "Buy" from BrokeragesAxsome Therapeutics, Inc. (AXSM) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 20 at 3:58 AM
Axsome Therapeutics, Inc. (AXSM) Upgraded to "Buy" by Zacks Investment ResearchAxsome Therapeutics, Inc. (AXSM) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM
Axsome Therapeutics Reports Third Quarter 2017 Financial ResultsAxsome Therapeutics Reports Third Quarter 2017 Financial Results
www.thestreet.com - November 8 at 6:42 PM
Axsome Therapeutics, Inc. (AXSM) Scheduled to Post Quarterly Earnings on MondayAxsome Therapeutics, Inc. (AXSM) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
Axsome Therapeutics (AXSM) and Kite Pharma (KITE) Critical SurveyAxsome Therapeutics (AXSM) and Kite Pharma (KITE) Critical Survey
www.americanbankingnews.com - October 31 at 7:16 PM

SEC Filings

Axsome Therapeutics (NASDAQ:AXSM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Axsome Therapeutics (NASDAQ:AXSM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Axsome Therapeutics (NASDAQ AXSM) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.